5-MeO-IsoqT

5-MeO-IsoqT
Clinical data
Other names	5-MeO-desethylisoquinuclidineT; Desethyl-17,18-secoibogaine
ATC code	None;
Identifiers
	IUPAC name 3-[2-(2-azabicyclo[2.2.2]octan-2-yl)ethyl]-5-methoxy-1H-indole;
PubChem CID	10016744;
ChemSpider	8192317;
Chemical and physical data
Formula	C18H24N2O
Molar mass	284.403 g·mol−1
3D model (JSmol)	Interactive image;
	SMILES COC1=CC2=C(C=C1)NC=C2CCN3CC4CCC3CC4;
	InChI InChI=1S/C18H24N2O/c1-21-16-6-7-18-17(10-16)14(11-19-18)8-9-20-12-13-2-4-15(20)5-3-13/h6-7,10-11,13,15,19H,2-5,8-9,12H2,1H3; Key:ACNCVCCDIUQDHS-UHFFFAOYSA-N;

5-MeO-IsoqT, also known as 5-MeO-desethylisoquinuclidineT or as desethyl-17,18-secoibogaine, is a tryptamine derivative and a deconstructed and simplified analogue of ibogaine.^[1] It is a derivative of ibogaine lacking the tetrahydroazepine ring but with the isoquinuclidine ring retained.^[1] Similarly to ibogaine and noribogaine, but unlike structurally related tryptamines like 5-MeO-DMT and 5-MeO-pip-T, 5-MeO-IsoqT is said to have insignificant activity as an agonist of the serotonin 5-HT_1A and 5-HT_2A receptors.^[1] 5-MeO-IsoqT was described in the scientific literature by Dalibor Sames and colleagues in 2024.^[1] Other closely related isoquinuclidine-tryptamines have also been described by David E. Olson and colleagues in 2021, for instance the ethyl-conserved 5-hydroxy and 5-methoxy analogues.^[2]

Quick facts Clinical data, Other names ...

See also